Resectable Hepatocellular Carcinoma Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Resectable Hepatocellular Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 30 trials

Recruiting
Phase 2

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

Advanced Unresectable Hepatocellular Carcinoma
Riboscience, LLC.220 enrolled3 locationsNCT07175441
Recruiting
Phase 1Phase 2

A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma
West China Hospital33 enrolled1 locationNCT07482059
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 1

18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

CholangiocarcinomaBenign Liver TumorAdult Hepatocellular Carcinoma+2 more
M.D. Anderson Cancer Center110 enrolled1 locationNCT02379377
Recruiting
Phase 1Phase 2

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Stage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Unresectable Hepatocellular Carcinoma+3 more
Mayo Clinic85 enrolled1 locationNCT03942328
Recruiting
Phase 1

Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

Unresectable Hepatocellular Carcinoma
Massachusetts General Hospital20 enrolled3 locationsNCT05096715
Recruiting
Not Applicable

Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma (HCC)
Bangladesh Medical University40 enrolled1 locationNCT07408804
Recruiting
Phase 1

MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.

Unresectable Hepatocellular Carcinoma (HCC)Hepatoma
Suzhou Mednovo Yi Medical Technology Co., Ltd.40 enrolled8 locationsNCT07391839
Recruiting
Phase 1Phase 2

A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaUnresectable Hepatocellular Carcinoma+4 more
Pfizer138 enrolled1 locationNCT07227012
Recruiting
Not Applicable

Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study

Unresectable Hepatocellular CarcinomaHCC - Hepatocellular Carcinoma
The University of Hong Kong30 enrolled1 locationNCT07305428
Recruiting
Phase 2

Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Cancer Institute and Hospital, Chinese Academy of Medical Sciences30 enrolled4 locationsNCT07239245
Recruiting
Phase 2

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

Hepatocellular CarcinomaUnresectable Hepatocellular Carcinoma
University of Miami30 enrolled1 locationNCT06902246
Recruiting
Phase 1

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Solid TumorsMetastatic Hepatocellular CarcinomaAdvanced Solid Tumors+11 more
Tyra Biosciences, Inc100 enrolled16 locationsNCT06915753
Recruiting

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

Unresectable Hepatocellular Carcinoma
Bayer300 enrolled20 locationsNCT06117891
Recruiting
Phase 2

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Locally Advanced Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8+6 more
Academic and Community Cancer Research United122 enrolled16 locationsNCT05168163
Recruiting
Phase 1

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Hepatocellular CarcinomaHepatocellular CancerResectable Hepatocellular Carcinoma
Jiping Wang, MD, PhD20 enrolled3 locationsNCT05701488
Recruiting

The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study

Unresectable Hepatocellular CarcinomaPsychological DistressHCC - Hepatocellular Carcinoma+2 more
Guilin Medical University, China700 enrolled5 locationsNCT07141056
Recruiting

Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension

Unresectable Hepatocellular Carcinoma
Zhiyong Huang60 enrolled1 locationNCT06280313
Recruiting

The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Sun Yat-sen University100 enrolled1 locationNCT07064681
Recruiting
Phase 3

Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

Unresectable Hepatocellular Carcinoma
Chengdu New Radiomedicine Technology Co. LTD.108 enrolled11 locationsNCT06900543